Laurus Labs (LAURUSLABS) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenues reached ₹1,195 Cr, up 1% year-over-year, with API (Onco-led) and ARV demand offset by subdued CDMO delivery and FDF declines.

• EBITDA stood at ₹171 Cr (14.3% margin), impacted by lower asset utilization and upfront costs in growth projects.

• Gross margin improved to 55.1%, both year-over-year and sequentially.

• Major rebranding initiative launched with the tagline "Chemistry for Better Living" to reinforce global positioning.

• Board approved unaudited financial results and appointed Mr. Ramesh Subrahmanian as an Independent Director.

Financial highlights

• Q1 FY25 revenue grew 1% year-over-year to ₹1,195 Cr; API growth (+11%) offset by CDMO (-14%) and FDF (-4%).

• Gross margin: 55.1%, up 450 bps year-over-year and 530 bps sequentially.

• EBITDA: ₹171 Cr, up 2% year-over-year, margin at 14.3%.

• Net profit after tax for Q1 FY25 was ₹12.21 crore, down from ₹28.40 crore in Q1 FY24.

• R&D spend: ₹64 Cr (5.4% of revenue), including CGT and animal health initiatives.

Outlook and guidance

• FY25 growth to be driven by medium/long-term contracts, late-phase NCE projects, and new assets coming online.

• Performance expected to improve in H2 FY25, with scheduled project deliveries for key late-phase NCE projects in Q4.

• Confident in maintaining gross margins around 50% and achieving 20% EBITDA margin for FY25.

• Net debt/EBITDA targeted to fall below 2.5x by March 2025.

• Board and management did not provide explicit forward-looking guidance in the reviewed materials.